AntiagingAtlanta

 
Testosterone Replacement Therapy TRT Hormone
     
 

by Dr. Randy Smith of Antiaging Atlanta

   

TRT for symptomatic hypogonadism does not appear to increase PSA levels nor the risk of prostate cancer development.

 

2016 Nov;118(5):731-741. doi: 10.1111/bju.13417. Epub 2016 Feb 24.

Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis.

Abstract

OBJECTIVE:

To review and quantify the association between endogenous and exogenous testosterone and prostate-specific antigen (PSA) and prostate cancer.

METHODS:

Literature searches were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Prospective cohort studies that reported data on the associations between endogenous testosterone and prostate cancer, and placebo-controlled randomized trials of testosterone replacement therapy (TRT) that reported data on PSA and/or prostate cancer cases were retained. Meta-analyses were performed using random-effects models, with tests for publication bias and heterogeneity.

RESULTS:

Twenty estimates were included in a meta-analysis, which produced a summary relative risk (SRR) of prostate cancer for an increase of 5 nmol/L of testosterone of 0.99 (95% confidence interval [CI] 0.96, 1.02) without heterogeneity (I² = 0%). Based on 26 trials, the overall difference in PSA levels after onset of use of TRT was 0.10 ng/mL (-0.28, 0.48). Results were similar when conducting heterogeneity analyses by mode of administration, region, age at baseline, baseline testosterone, trial duration, type of patients and type of TRT. The SRR of prostate cancer as an adverse effect from 11 TRT trials was 0.87 (95% CI 0.30; 2.50). Results were consistent across studies.

CONCLUSIONS:

Prostate cancer appears to be unrelated to endogenous testosterone levels. TRT for symptomatic hypogonadism does not appear to increase PSA levels nor the risk of prostate cancer development. The current data are reassuring, although some caution is essential until multiple studies with longer follow-up are available.

© 2016 The Authors BJU International © 2016 BJU International Published by John Wiley & Sons Ltd.

KEYWORDS:

meta-analysis; prostate cancer; prostate-specific antigen; testosterone

PMID:
26779889
DOI:
10.1111/bju.13417
     
  Personal Message from Dr. Smith
     
   

My primary goal at AntiagingAtlanta is to enhance your quality of life through providing a comprehensive approach to antiaging medicine.

I am committed to providing you with the best Antiaging Medicine program available.

Call me today and schedule your Antiaging Medicine evaluation.

Sincerely,

Dr. Randy Smith

     
     

 

Antiaging Atlanta
12600 Deerfield Parkway
Suite 100
Alpharetta, Georgia 30004

Phone: 678-566-3602

Call today today and speak with Dr. Smith to schedule your personal Agntiaging Medicine evaluation.

www.antiagingatlanta.com

Getting Started

To unsubscribe to our newsletter email Dr. Smith at:

Dr. Smith